Mary Jo Lechowicz - Concepedia

Author

Mary Jo Lechowicz

Also Known As

M J Lechowicz, M. Lechowicz, M.J. Lechowicz, Mary J Lechowicz, Mary J. Lechowicz, Mary Jo Lechowicz, Mary Lechowicz, Mary.Jo Lechowicz, Mary Jo Lechowicz

226

Publications

Citations

H-Index

Concepts

All Affiliations

Emory University Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Washington University in St. Louis Winship Cancer Institute

About

Mary Jo Lechowicz is an author at Emory University specializing in medicine, immunology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	18	1.6K
2	Health Sciences	6	6	211
3	Public Health	2	2	207
4	African American Studies	1	1	55
5	Allergy	1	1	30

Mary Jo Lechowicz

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown, Journal of Clinical Oncology	2011	630
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, The Lancet Oncology Cutaneous T-cell LymphomaLymphoid NeoplasiaMedicinePathologyMogamulizumab Versus Vorinostat	2018	621
International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease David C. Fajgenbaum, Thomas S. Uldrick, Adam Bagg, Blood	2017	590
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease Frits van Rhee, Peter M. Voorhees, Angela Dispenzieri, Blood	2018	394
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816 Oliver W. Press, Hongli Li, Heiko Schöder, Journal of Clinical Oncology	2016	262
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study Kieron Dunleavy, Michelle A. Fanale, Jeremy S. Abramson, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaSingle-arm Phase 2MedicineImmunology	2018	226
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease Frits van Rhee, Éric Oksenhendler, Gordan Srkalović, Blood Advances	2020	197
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC Elise A. Olsen, Sean Whittaker, Rein Willemze, Blood	2021	158
Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States Abeer N. AbouYabis, Pareen J. Shenoy, Mary Jo Lechowicz, Leukemia & lymphoma/Leukemia and lymphoma ImmunodeficienciesImmunologyPathologyImmunotherapyUnited States	2008	152
The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study Steven I. Park, Steven M. Horwitz, Francine M. Foss, Cancer	2019	144

Page 1